- Home
- NVCR
NVCR
NovoCure Limited
as 03-28-2025 4:00pm EST
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Switzerland |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 2.3B | IPO Year: | 2015 |
| Target Price: | $37.50 | AVG Volume (30 days): | 840.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.70 - $34.13 | Next Earning Date: | 05-01-2025 |
| Revenue: | $605,220,000 | Revenue Growth: | 18.82% |
| Revenue Growth (this year): | 3.41% | Revenue Growth (next year): | 9.24% |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Weinberg Uri | NVCR | Chief Innovation Officer | Mar 3 '25 | Sell | $18.67 | 4,905 | $92,020.26 | 166,511 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Mar 3 '25 | Sell | $18.54 | 2,527 | $46,841.23 | 143,673 | |
| Cordova Ashley | NVCR | Chief Executive Officer | Mar 3 '25 | Sell | $18.54 | 2,053 | $38,055.02 | 204,005 | |
| Paravasthu Mukund | NVCR | Chief Operating Officer | Mar 3 '25 | Sell | $18.54 | 250 | $4,634.08 | 29,173 | |
| Weinberg Uri | NVCR | Chief Innovation Officer | Feb 28 '25 | Sell | $18.55 | 4,637 | $86,949.24 | 166,511 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Feb 27 '25 | Sell | $19.59 | 30,072 | $592,513.68 | 143,673 | |
| Puri Michal Nath | NVCR | Chief Human Resources Officer | Feb 27 '25 | Sell | $20.24 | 2,774 | $55,545.55 | 108,706 | |
| Cordova Ashley | NVCR | Chief Executive Officer | Feb 27 '25 | Sell | $19.59 | 26,988 | $532,252.59 | 204,005 | |
| Leupin Nicolas | NVCR | Chief Medical Officer | Feb 27 '25 | Sell | $20.24 | 1,982 | $39,687.13 | 50,294 | |
| Paravasthu Mukund | NVCR | Chief Operating Officer | Feb 27 '25 | Sell | $19.59 | 4,028 | $79,375.01 | 29,173 |
Latest NovoCure Limited News
NVCR Breaking Stock News: Dive into NVCR Ticker-Specific Updates for Smart Investing
Business Wire
25 days ago
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
MT Newswires
a month ago
Novocure Insider Sold Shares Worth $266,126, According to a Recent SEC Filing
MT Newswires
a month ago
Novocure Insider Sold Shares Worth $296,257, According to a Recent SEC Filing
Simply Wall St.
a month ago
NovoCure Full Year 2024 Earnings: EPS Misses Expectations
GuruFocus.com
a month ago
NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...
Motley Fool
a month ago
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
Zacks
a month ago
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say
MT Newswires
a month ago
NovoCure's Q4 Loss Widens, Revenue Rises
Compare NVCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.